A Phase II Randomized, Placebo-Controlled Clinical Trial of Purified Isoflavones in Modulating Steroid Hormones in Men Diagnosed With Localized Prostate Cancer
- 7 November 2007
- journal article
- research article
- Published by Taylor & Francis Ltd in Nutrition and Cancer
- Vol. 59 (2), 163-168
- https://doi.org/10.1080/01635580701432678
Abstract
Our purpose was to evaluate the safety and effectiveness of purified isoflavones in producing an increase in plasma isoflavones and a corresponding change in serum sex hormone binding globulin (SHBG) and steroid hormone levels in men diagnosed with early stage prostate cancer. In this Phase II randomized, double-blinded, placebo-controlled trial, 53 prostate cancer patients with a Gleason score of 6 or below were supplemented with 80 mg purified isoflavones or placebo for 12 weeks. Changes in plasma isoflavones, serum steroid hormones, and safety markers were analyzed from baseline to 12 wk. A total of 50 subjects completed the study. Although significant increases in plasma isoflavones (P < 0.001) was observed with no clinical toxicity, the corresponding modulation of serum SHBG, total estradiol, and testosterone in the isoflavone-treated group compared to men receiving placebo was nonsignificant. Increasing plasma isoflavones failed to produce a corresponding modulation of serum steroid hormone levels in men with localized prostate cancer. The study establishes the need to explore other potential mechanisms by which prolonged and consistent purified isoflavone consumption may modulate prostate cancer risk.Keywords
This publication has 38 references indexed in Scilit:
- Estrogens and Mechanisms of Prostate Cancer ProgressionAnnals of the New York Academy of Sciences, 2006
- Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United StatesJNCI Journal of the National Cancer Institute, 2006
- Antitumor and Antimetastatic Activities of Docetaxel Are Enhanced by Genistein through Regulation of Osteoprotegerin/Receptor Activator of Nuclear Factor-κB (RANK)/RANK Ligand/MMP-9 Signaling in Prostate CancerCancer Research, 2006
- Genistein Represses Telomerase Activity via Both Transcriptional and Posttranslational Mechanisms in Human Prostate Cancer CellsCancer Research, 2006
- The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinaseAPMIS, 2006
- Serum Testosterone and the Risk of Prostate Cancer: Potential Implications for Testosterone TherapyCancer Epidemiology, Biomarkers & Prevention, 2005
- Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activityInternational Journal of Urology, 2005
- A Concentrated Aglycone Isoflavone Preparation (GCP) That Demonstrates Potent Anti-Prostate Cancer Activity In vitro and In vivo Clinical Cancer Research, 2004
- High-grade prostatic intraepithelial neoplasiaLaboratory Investigation, 2004
- The Role of Soy Products in Reducing Risk of CancerJNCI Journal of the National Cancer Institute, 1991